AI Science Tracker
EN

PLAC8 is an innovative biomarker for immunotherapy participating in remodeling the immune microenvironment of renal clear cell carcinoma.

Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; School of Pediatrics, Nanjing Medical University, Nanjing, China. · 30 Oct 2023 · medicine

Discovery

PLAC8 is an innovative biomarker for immunotherapy participating in remodeling the immune microenvironment of renal clear cell carcinoma.

Source check: Source checked. Not independent scientific confirmation.

Finding: Original full text, Methods/Results: TCGA expression analyses and external cohort support PLAC8 immune associations; cell-line knockdown tested proliferation, migration and invasion. Immune-therapy response is computationally inferred, not demonstrated in a treated cohort. AI role: Machine-learning prognostic model based on PLAC8-related molecules. The article appeared in Frontiers In Oncology.

Technology: Machine-learning prognostic model based on PLAC8-related molecules

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Machine-learning prognostic model based on PLAC8-related molecules
Test and result
Original full text, Methods/Results: TCGA expression analyses and external cohort support PLAC8 immune associations; cell-line knockdown tested proliferation, migration and invasion. Immune-therapy response is computationally inferred, not demonstrated in a treated cohort.
Limitation / still unknown
The result is limited to the described dataset, cohort, experimental system, or validation design; generalization beyond that scope and downstream real-world benefit are not established. Author affiliation was not stated in the reviewed abstract or metadata.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1207551/full · https://europepmc.org/article/MED/38023190 · https://pubmed.ncbi.nlm.nih.gov/38023190/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.